EVANSTON, Ill., Sept. 17 /PRNewswire-FirstCall/ --
Northfield Laboratories Inc. (Nasdaq: NFLD), a leading developer of an oxygen-
carrying blood substitute for trauma and elective surgery situations, today
announced that IVS Associates, the independent inspector of elections at
Northfield's September 13 annual meeting of shareholders, had delivered its
preliminary report on the voting results from the meeting.
According to the IVS report, each of Northfield's seven director nominees
received more than 6.2 million votes, representing approximately 61% of the
shares present and entitled to vote at the annual meeting. Each of the two
director nominees proposed by dissident shareholder C. Robert Coates received
fewer than 3.8 million votes. The proposal with respect to the ratification
of the appointment of Northfield's independent auditors was approved by the
required majority vote.
Northfield indicated that it had further adjourned its annual meeting
until Tuesday, September 24, 2002, at 10:00 a.m., local time, at its corporate
offices in Evanston, Illinois, in order to permit IVS to complete its
certification process.
Statements in this release that are not strictly historical are "forward-
looking" statements that are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's
actual results in the future to differ materially from expected results. These
risks include, among others: competition from other blood substitute products;
the company's ability to obtain regulatory approval to market PolyHeme(TM)
commercially; the company's and/or its representative's ability to
successfully market and sell PolyHeme; the company's ability to manufacture
PolyHeme in sufficient quantities; the company's ability to obtain an adequate
supply of raw materials; the company's ability to maintain intellectual
property protection for its proprietary product and to defend its existing
intellectual property rights from challenges by third parties; the
availability of capital to finance planned growth; and the extent to which the
hospitals and physicians using PolyHeme are able to obtain third-party
reimbursement, as described in the company's filings with the Securities and
Exchange Commission.
Visit the Northfield website at: http://www.northfieldlabs.com
SOURCE Northfield Laboratories Inc.
 back to top
Related links:
http://www.northfieldlabs.com
CONTACT:
Steven A. Gould, M.D., Chief Executive
Officer of Northfield Laboratories, +1-847-864-3500, Investors,
Lisa Fortuna, +1-312-640-6779, or Media, Cindy Martin,
+1-312-640-6741, both of FRB Weber Shandwick
|
